The 36-month beta value for RARE is at 0.68. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 6 rating it as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for RARE is 77.02M, and currently, shorts hold a 5.69% of that float. The average trading volume for RARE on May 02, 2024 was 697.61K shares.
RARE) stock’s latest price update
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)’s stock price has plunge by 1.79relation to previous closing price of 42.54. Nevertheless, the company has seen a -2.21% plunge in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-25 that NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, May 2, 2024, to discuss its financial results and corporate update for the quarter ending March 31, 2024.
RARE’s Market Performance
Ultragenyx Pharmaceutical Inc. (RARE) has experienced a -2.21% fall in stock performance for the past week, with a -7.06% drop in the past month, and a -1.84% drop in the past quarter. The volatility ratio for the week is 3.38%, and the volatility levels for the past 30 days are at 4.86% for RARE. The simple moving average for the last 20 days is -5.59% for RARE stock, with a simple moving average of 2.81% for the last 200 days.
Analysts’ Opinion of RARE
Many brokerage firms have already submitted their reports for RARE stocks, with RBC Capital Mkts repeating the rating for RARE by listing it as a “Outperform.” The predicted price for RARE in the upcoming period, according to RBC Capital Mkts is $77 based on the research report published on April 22, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see RARE reach a price target of $72. The rating they have provided for RARE stocks is “Overweight” according to the report published on December 08th, 2023.
Credit Suisse gave a rating of “Outperform” to RARE, setting the target price at $96 in the report published on June 14th of the previous year.
RARE Trading at -9.07% from the 50-Day Moving Average
After a stumble in the market that brought RARE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.24% of loss for the given period.
Volatility was left at 4.86%, however, over the last 30 days, the volatility rate increased by 3.38%, as shares sank -8.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.55% lower at present.
During the last 5 trading sessions, RARE fell by -2.21%, which changed the moving average for the period of 200-days by -2.35% in comparison to the 20-day moving average, which settled at $45.67. In addition, Ultragenyx Pharmaceutical Inc. saw -9.45% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RARE starting from Crombez Eric, who sale 142 shares at the price of $44.10 back on Apr 18 ’24. After this action, Crombez Eric now owns 48,785 shares of Ultragenyx Pharmaceutical Inc., valued at $6,262 using the latest closing price.
Kassberg Thomas Richard, the CBO & EVP of Ultragenyx Pharmaceutical Inc., sale 11,509 shares at $49.93 during a trade that took place back on Mar 11 ’24, which means that Kassberg Thomas Richard is holding 252,823 shares at $574,644 based on the most recent closing price.
Stock Fundamentals for RARE
Current profitability levels for the company are sitting at:
- -1.31 for the present operating margin
- 0.9 for the gross margin
The net margin for Ultragenyx Pharmaceutical Inc. stands at -1.4. The total capital return value is set at -0.47. Equity return is now at value -193.23, with -39.80 for asset returns.
Based on Ultragenyx Pharmaceutical Inc. (RARE), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -11.0. The debt to equity ratio resting at 0.16. The interest coverage ratio of the stock is -8.62.
Currently, EBITDA for the company is -516.85 million with net debt to EBITDA at 0.32. When we switch over and look at the enterprise to sales, we see a ratio of 7.82. The receivables turnover for the company is 5.92for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.61.
Conclusion
In conclusion, Ultragenyx Pharmaceutical Inc. (RARE) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
